Wound Management News

Ophthalmic application of beremagene geperpavec was successful in treating recurrent cicatrizing conjunctivitis in one patient with dystrophic epidermolysis bullosa, according to a study.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

People with HIV who were treated with tecovirimat within the first 7 days of mpox symptom onset were 13 times less likely to progress to severe mpox disease compared with those not treated or treated late, a recent study found.

Vyjuvek, the first FDA-approved treatment for dystrophic epidermolysis bullosa, has received a permanent J-code from the Centers for Medicare and Medicaid Services, Krystal Biotech announced in a press release.

The Japanese Ministry of Health, Labour and Welfare has granted Vyjuvek an orphan drug designation for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release.

Vibrio cases and deaths in Florida spiked last year after Hurricane Ian, lending credence to concerns that larger, longer, warmer tropical storms may increase the risk for viral infections, according to a study.

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA Dermatology.

Results from DETECT, the phase 3 study that supported the FDA approval of NexoBrid for the treatment of severe thermal burns, was recently published in the Journal of Burn Care & Research, Vericel announced in a release.

On Sept. 1, the CDC issued a health advisory concerning an increased rate of infections in the United States of a flesh-eating bacterium called Vibrio vulnificus.